Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 2:54 PM
Ignite Modification Date:
2025-12-24 @ 2:54 PM
NCT ID:
NCT06015659
Brief Summary:
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.
The names of the study drugs involved in this study are:
* ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
* Gemcitabine (a nucleoside metabolic inhibitor)
Detailed Description:
This is an open label, single arm phase 2 trial evaluating ZN-c3 combined with gemcitabine in second-line advanced pancreatic cancer. There are lab experiments that show that pancreatic cancer cells can respond to a combination of ZN-c3, an experimental drug, with gemcitabine.
The U.S. Food and Drug Administration (FDA) has not approved ZN-c3 as a treatment for any disease. The FDA has approved gemcitabine as a treatment option for advanced pancreatic cancer.
The research study procedures include screening for eligibility, study treatment including evaluations and follow up visits, radiological scans (Computerized Tomography, Magnetic Resonance Imaging, or Positron Emission Tomography), blood tests, electrocardiogram, and tumor biopsy.
It is expected that about 34 people will take part in this research study.
The Lustgarten Foundation for Pancreatic Research and Stand Up to Cancer are supporting this research study by providing funding to conduct the study. Zentalis is supplying the study drug, ZN-c3.
Study:
NCT06015659
Study Brief:
Protocol Section:
NCT06015659